Liver function tests are routine blood panels that provide essential insights into how well the liver is functioning. Among the most common markers measured are alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These enzymes normally reside inside liver cells. When liver tissue experiences stress, inflammation, or injury, these enzymes leak into the bloodstream, causing elevated blood levels that prompt further clinical evaluation.
The Role of Routine Liver Enzymes
Elevated liver enzymes like ALT and AST are often discovered incidentally during routine metabolic panels or targeted evaluations. Current medical guidelines recommend targeted screening for adults with specific risk factors, such as type 2 diabetes, obesity, excess adiposity with metabolic risk factors, or unexplained liver enzyme abnormalities [4]. Evaluating these markers helps clinicians detect early signs of stress before more severe complications develop.
Metabolic Dysfunction and Liver Health
Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly referred to as NAFLD — is increasingly common worldwide and is frequently linked to cardiometabolic conditions like type 2 diabetes and hazardous alcohol use [2, 4]. When investigating abnormal liver tests, the central diagnostic task is not merely detecting fat accumulation, but identifying patients with clinically important fibrosis who require closer monitoring and treatment intensification [4]. Initial assessment typically involves defining the metabolic context, quantifying alcohol exposure, and excluding competing liver conditions [4].
Non-Invasive Fibrosis Assessment
In addition to standard blood tests, modern clinical pathways utilize advanced non-invasive testing to stage liver disease without always requiring a biopsy. Methods such as the enhanced liver fibrosis (ELF) test and liver stiffness measurement (LSM) help assess the risk of advanced scarring in at-risk populations [2]. Similarly, sequential testing models and clinical scoring indices, such as the FIB-4 index, allow clinicians to reliably stratify patient risk and identify individuals who may be at risk for advanced complications like clinically significant portal hypertension [4, 8].
The Thyroid-Liver Connection
The liver and the thyroid gland share a complex, bidirectional relationship that plays a major role in overall metabolic regulation [5]. Thyroid hormones regulate hepatic lipid handling, glucose metabolism, and energy balance, while the liver is responsible for clearing and activating thyroid hormones [5]. Research indicates that thyroid dysfunction, including both overt disorders and subtle hormonal variations, can significantly impact hepatic health, contribute to steatotic liver disease, and even mimic acute liver injury [1, 5, 6]. Consequently, clinicians evaluating unexplained liver test abnormalities often review thyroid function to ensure an accurate diagnosis before determining a treatment plan [1].
Sources
- [1] Thyroid Disease-Induced Hepatic Dysfunction: A Clinical Puzzle. PubMed
- [2] Using the enhanced liver fibrosis test to identify disease in at-risk populations. PubMed
- [3] Association of Euthyroid Thyroid Hormone Levels with Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. PubMed
- [4] Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Diagnostic Pathways, Noninvasive Fibrosis Assessment, and Therapeutic Strategies. PubMed
- [5] Thyroid-Liver Axis: Mechanistic Insights and Clinical Implications. PubMed
- [6] Hypothyroidism in Nonalcoholic Fatty Liver Disease. PubMed
- [7] Clinically Inferred Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Association with Atrial Fibrillation Subtypes. PubMed
- [8] Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis. PubMed